GlassScriptPhysician profile
David R Andes
NPI 1154398857
$19,892.66
in general payments reported to CMS, 2019-2025
8 companies · $6,720 in 2025
The $6,720 reported for 2025 was more than what 91% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $5,283 · 2021: $1,640 · 2022: $1,722 · 2023: $257 · 2024: $3,070 · 2025: $6,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,457 · Travel and Lodging: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,457.00 |
| Travel and Lodging | $1,589.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $5,153.50 | 2019-2025 | Cresemba |
| Melinta Therapeutics, LLC | $4,600.00 | 2024-2025 | Rezzayo |
| Genentech, INC. | $4,129.16 | 2025 | |
| Merck Sharp & Dohme LLC | $3,400.00 | 2020-2021 | |
| F. Hoffmann-La Roche Ag | $2,610.00 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Andes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.